Free tool
FAERS Monitor: Renacidin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019481 or its brand name (Renacidin, Citric Acid, Gluconolactone, Magnesium Carbonate). Reports on generic versions are filed under their own applications.
Reports
17
Serious
14
82% of reports
Hospitalization
9
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cardio-respiratory arrest2
- device failure2
- fall2
- haematuria2
- nephrolithiasis2
- septic shock2
- urinary tract infection2
- acute respiratory distress syndrome1
- apnoea1
- aspiration1
- asthenia1
- balance disorder1
- bladder perforation1
- blood magnesium increased1
- blood sodium decreased1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2020 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,142 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bladder perforation | 1 | 3208.5 | 477.9 | 799 |
| blood magnesium increased | 1 | 1374.6 | 205.1 | 342 |
| device failure | 2 | 162.5 | 44.2 | 180 |
| apnoea | 1 | 158.9 | 23.7 | 39 |
| aspiration | 1 | 113.0 | 16.9 | 27 |
| haematuria | 2 | 72.3 | 19.7 | 78 |
| acute respiratory distress syndrome | 1 | 70.0 | 10.4 | 17 |
| blood sodium decreased | 1 | 65.7 | 9.8 | 15 |
| cardio-respiratory arrest | 2 | 59.2 | 16.1 | 64 |
| septic shock | 2 | 56.9 | 15.5 | 61 |
| nephrolithiasis | 2 | 54.0 | 14.7 | 58 |
| urinary tract infection | 2 | 14.5 | 3.9 | 14 |
| balance disorder | 1 | 14.3 | 2.1 | 3 |
| fall | 2 | 7.4 | 2.0 | 6 |
| asthenia | 1 | 3.3 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.